MedTrace Logo

Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study

NCT06249269 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 198

Last updated 2025-12-02

No results posted yet for this study

Summary

Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It results in high healthcare costs and significant morbidity, especially for patients with severe symptoms. The RASTA-AF randomized control trial (RCT) is designed to answer the following question: does vigorous treatment of AF with aggressive risk factor management plus catheter ablation reduce AF-related outcomes as compared to catheter ablation plus usual care in patients with symptomatic AF and risk factors that promote AF.

This study is a multicenter, prospective cohort study that will enrol patients who decline participation in the RASTA-AF RCT but agree to be followed in a registry. The objective of RASTA-Cohort is to determine whether patients who decline participation in the RASTA-AF RCT have different clinical characteristics and quality of life than patients who accept participation in the study, and whether they suffer from worse AF-related outcomes than patients in the RCT.

Conditions

  • Atrial Fibrillation, Paroxysmal or Persistent

Sponsors & Collaborators

  • Nova Scotia Health Research Fund

    collaborator UNKNOWN

  • Ratika Parkash

    lead OTHER

Principal Investigators

  • Ratika Parkash, MD, FRCPC · Nova Scotia Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06249269 on ClinicalTrials.gov